Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI LODR
Date of Board Meeting / Approval: August 13, 2026
Audit Opinion: Unmodified limited review report issued by S.R. Batliboi & Co. LLP
Auditor’s Comment: No material misstatements found; includes reliance on other auditors for subsidiary reviews
Key Financial Highlights [in ₹ lakhs]:
Consolidated Results:
Revenue from Operations: ₹240,669 lakhs (Previous quarter: ₹219,072 lakhs; Year-ago quarter: ₹206,408 lakhs)
Total Income: ₹240,669 lakhs
Net Profit: ₹32,296 lakhs (Previous quarter: ₹34,222 lakhs; Year-ago quarter: ₹30,797 lakhs)
EPS: Basic - ₹3.32; Diluted - ₹3.30
Other Comprehensive Income: Loss of ₹481 lakhs
Total Comprehensive Income: ₹31,815 lakhs
Paid-up equity share capital: ₹97,324 lakhs
Standalone Results:
Revenue from Operations: ₹87,502 lakhs (Previous quarter: ₹82,424 lakhs; Year-ago quarter: ₹77,379 lakhs)
Total Income: ₹87,502 lakhs
Net Profit: ₹16,760 lakhs (Previous quarter: ₹20,321 lakhs; Year-ago quarter: ₹16,603 lakhs)
EPS: Basic - ₹1.72; Diluted - ₹1.71
Other Comprehensive Income: Loss of ₹435 lakhs
Total Comprehensive Income: ₹16,325 lakhs
Paid-up equity share capital: ₹97,324 lakhs
Reserves (other equity): ₹7,96,746 lakhs (as of March 31, 2026)
Segment-wise Performance:
The Group's business activity primarily falls within a single reportable business segment 'Medical and Healthcare Services' and geographical segment 'India'.
Corporate Actions:
Not Specified
Change in Senior Management Personnel:
Appointments:
- Mr. Ajay Vij appointed as Director - Chief Supply Chain & Procurement Officer, effective August 14, 2026 (full-time employment)
- Mr. Pawan Kumar Marella appointed as Senior Director - Chief Experience & Brand Officer, effective August 17, 2026 (full-time employment)
Resignation:
- Dr. N. Venkatesan, Senior Director & Chief Procurement Officer, resigned effective August 31, 2026, to pursue opportunities outside the organization
Capital Expenditure Approval:
Approved capital expenditure of ~₹425 Crore for construction of 'Tower 3' at Max Super Speciality Hospital, Vaishali, operated by Crosslay Remedies Limited (wholly-owned subsidiary).
- Existing capacity: ~387 beds
- Proposed addition: ~202 census beds + ~48 non-census beds
- Commissioning target: November 2029
- Mode of financing: Combination of internal accruals and borrowings
- Rationale: Cater to healthcare needs in Ghaziabad region, Uttar Pradesh
Other Significant Information:
- The company acquired 58.26% equity stake in Kalinga Hospital Limited on May 18, 2026, for ₹29,787 lakhs (250-bed hospital in Bhubaneswar, Odisha)
- The company acquired 100% Class A equity shares of Yerawada Properties Private Limited on June 30, 2026, for ₹68,792 lakhs (1.68-acre land parcel in Pune)
- MHC Global Healthcare (Nigeria) Limited in voluntary liquidation, deemed dissolved upon expiry of three months from July 29, 2026
- The company granted 2,15,000 stock options under MHIL ESOP 2022 during the quarter
- Exceptional items for previous year included impact of New Labour Codes (₹3,390 lakhs consolidated, ₹1,564 lakhs standalone) and provision for stamp duty on merger (₹1,434 lakhs consolidated)